STOCK TITAN

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Ironwood Pharmaceuticals (Nasdaq: IRWD) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, December 4, 2024, at 12:30 p.m. ET, taking place at the Lotte New York Palace.

The event will be accessible via live webcast through the Investors section of Ironwood's website. Following the conference, a replay of the fireside chat will be made available on the company's website at www.ironwoodpharma.com.

Ironwood Pharmaceuticals (Nasdaq: IRWD) ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. La direzione dell'azienda parteciperà a una chiacchierata informale mercoledì 4 dicembre 2024, alle 12:30 ora orientale, che si svolgerà presso il Lotte New York Palace.

L'evento sarà accessibile in diretta tramite webcast attraverso la sezione Investitori del sito di Ironwood. Dopo la conferenza, una registrazione della chiacchierata informale sarà disponibile sul sito dell'azienda all'indirizzo www.ironwoodpharma.com.

Ironwood Pharmaceuticals (Nasdaq: IRWD) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La dirección de la empresa participará en una charla informal el miércoles 4 de diciembre de 2024 a las 12:30 p.m. ET, que se llevará a cabo en el Lotte New York Palace.

El evento será accesible a través de una transmisión en vivo en la sección de Inversores de la página web de Ironwood. Después de la conferencia, se podrá acceder a una repetición de la charla informal en el sitio de la empresa en www.ironwoodpharma.com.

아이언우드 제약(Ironwood Pharmaceuticals, Nasdaq: IRWD)이 파이퍼 샌들러 제36회 연례 헬스케어 콘퍼런스에 참가한다고 발표했습니다. 회사의 경영진은 2024년 12월 4일 수요일 오후 12시 30분(동부 표준시)에 롯데 뉴욕 팰리스(Lotte New York Palace)에서 진행되는 대화에 참여할 예정입니다.

이 행사는 아이언우드 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트로 볼 수 있습니다. 컨퍼런스 후에는 회사 웹사이트인 www.ironwoodpharma.com에서 대화 재생들을 확인할 수 있습니다.

Ironwood Pharmaceuticals (Nasdaq: IRWD) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. La direction de l'entreprise participera à une discussion informelle le mercredi 4 décembre 2024 à 12h30 ET, qui aura lieu au Lotte New York Palace.

L'événement sera accessible via une diffusion en direct sur la section Investisseurs du site web d'Ironwood. Après la conférence, un enregistrement de la discussion sera disponible sur le site de l'entreprise à l'adresse www.ironwoodpharma.com.

Ironwood Pharmaceuticals (Nasdaq: IRWD) hat seine Teilnahme an der 36. Jahreskonferenz im Gesundheitswesen von Piper Sandler bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 4. Dezember 2024, um 12:30 Uhr ET an einem informellen Gespräch im Lotte New York Palace teilnehmen.

Die Veranstaltung wird über einen Live-Webcast im Investorenbereich der Ironwood-Website zugänglich sein. Nach der Konferenz wird eine Wiederholung des informellen Gesprächs auf der Website des Unternehmens unter www.ironwoodpharma.com verfügbar sein.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com



Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When is Ironwood Pharmaceuticals (IRWD) presenting at the Piper Sandler Healthcare Conference 2024?

Ironwood Pharmaceuticals (IRWD) will present at the Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:30 p.m. ET.

Where can I watch Ironwood Pharmaceuticals' (IRWD) Piper Sandler Conference presentation?

The presentation can be viewed via live webcast through the Investors section of Ironwood's website at www.ironwoodpharma.com, with a replay available after the conference.

Where is the Piper Sandler Healthcare Conference 2024 being held for IRWD's presentation?

The conference will be held at the Lotte New York Palace.

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

554.76M
157.19M
1.68%
105.53%
6.85%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON